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Current guidelines recommend that caffeinated products should be avoided for at least 12
hours prior to regadenoson administration. We intended to examine the effect of caffeine
consumption and of timing of last dose on hemodynamic effects after regadenoson adminis-
tration for cardiac stress testing.
Methods
332 subjects undergoing regadenoson stress testing were enrolled. Baseline characteris-
tics, habits of coffee/caffeine exposure, baseline vital signs and change in heart rate, blood
pressure, percent of maximal predicted heart rate, and percent change in heart rate were
prospectively collected.
Results
Non-coffee drinkers (group 1) (73 subjects) and subjects who last drank coffee >24 hours
(group 3) (139 subjects) prior to regadenoson did not demonstrate any difference in systolic
blood pressure, heart rate change, maximal predicted heart rate and percent change in
heart rate. Systolic blood pressure change (15.2±17.1 vs. 7.2±10.2 mmHg, p = 0.001),
heart rate change (32.2±14 vs. 27.3±9.6 bpm, p = 0.038) and maximal predicted heart rate
(65.5±15.6 vs. 60.7±8.6%, p = 0.038) were significantly higher in non-coffee drinkers (group
1) compared to those who drank coffee 12–24 hours prior (group 2) (108 subjects). Subjects
who drank coffee >24 hours prior (group 3) exhibited higher systolic blood pressure change
(13±15.8 vs. 7±10.2, p = 0.007), and heart rate change (32.1±15.3 vs. 27.3±9.6, p = 0.017)
as compared to those who drank coffee 12–24 hours prior to testing (group 2).
Conclusions
Caffeine exposure 12–24 hours prior to regadenoson administration attenuates the vasoac-
tive effects of regadenoson, as evidenced by a blunted rise in heart rate and systolic blood
pressure. These results suggest that caffeine exposure within 24 hours may reduce the
effects of regadenoson administered for vasodilatory cardiac stress testing.
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Introduction
Myocardial perfusion imaging (MPI) has been extensively used for detecting coronary artery
disease, assessing viable myocardium, and evaluating the effect of different therapeutic inter-
ventions [1]. Vasodilator stress testing accounts for up to 45% of MPI studies [2]. Adenosine
and dipyridamole have been the main vasodilators used for stress testing until 2008 when rega-
denoson was approved by the FDA [3]. Regadenoson is a selective adenosine A2A receptor
agonist. It has a very low affinity for A1 adenosine receptors and almost no affinity for A2B
and A3 adenosine receptors. Regadenoson’s selectivity for A2A receptors results in increased
vasodilation and subsequently increased coronary blood flow (CBF). It is administered at a
fixed dose of 0.4mg as an intravenous bolus. It has a rapid onset of action and a short duration
of action with maximal plasma concentration achieved within 1 to 4 minutes after administra-
tion and an initial half-life of 2 to 4 minutes. [4–6].
The American Society of Nuclear cardiology recommends against the consumption of caf-
feinated food andbeverages or foods containing other methylxanthines (chocolate) for at least
12 hours prior to regadenoson administration (ASNC 2009). Caffeine, a (1,3,7-trimethyl-
xanthine), is a non-selective competitive inhibitor of all adenosine receptors particularly A2A
receptors [7,8].
Few studies assessed the interaction of regadenoson and caffeine. In conscious dogs, intrave-
nous administration of caffeine at 1–10 mg/kg, followed by regadenoson injection 45 minutes
later, did not significantly affect regadenoson induced coronary blood flow (CBF), but reduced
the duration of the 2-fold increase in CBF. It also blunted heart rate and blood pressure change
[9]. In a randomized, placebo-controlled, double blind and crossover pilot study of healthy
subjects, Gaemperli et al. showed that moderate caffeine intake 2 hours prior to regadenoson
administration did not affect myocardial blood flow (MBF) and blood pressure response but
resulted in a blunted heart rate response [10]. In contrast another randomized placebo con-
trolled study demonstrated that administration of 200 or 400 mg of caffeine 90 minutes before
regadenoson significantly reduced the number of segments with reversible defects by MPI [11].
The effect and duration of caffeine exposure on blood pressure, heart rate, and percent of
maximal predicted heart rate among subjects undergoing pharmacological stress testing with
regadenoson is not clear. We hypothesized that chronic caffeine intake with only 12–24 hours
cessation prior to regadenoson stress testing according to drug labeling recommendation,
affects maximal heart rate and blood pressure response as compared to non-caffeine consump-
tion or more prolonged interruption. The aim of the current study is to assess the effect of
habitual caffeine consumption on blood pressure, heart rate, percentage of predicted heart rate




The study protocol was approved by the Indiana University institutional review board for
research. Written informed consent was obtained from all subjects. Subjects referred for rega-
denoson stress testing were enrolled. Patients with combined exercise and regadenoson stress
testing were excluded from analysis. As per the protocol of our institution, all patients were
asked to not consume caffeinated beverages or xanthine containing foods for at least 12 hours
prior to study. Moreover, all patients were asked to take their routine daily medications. Base-
line demographic data and medical comorbidities were collected on all subjects. Information
on amount, frequency, and last exposure to caffeine, chocolate, and caffeinated soft drinks
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were collected prospectively prior to performance of cardiac stress test. Caffeine exposure was
classified according to none recently, last exposure of at least one cup of coffee 12–24 hours
prior to regadenoson stress test, and>24 hours prior to stress test. Consumption of one cup of
black or green tea was considered equal to one cup of coffee, and subjects who consumed tea
were included in the coffee consumption group for analysis. Subjects’ heart rate (HR), and
blood pressure were recorded at baseline instantaneously before administration of regadeno-
son. Subjects remained in a supine position throughout the test. Change in heart rate (chan-
geHR) during the stress test was calculated by subtracting resting (restingHR) from peak heart
rate (peakHR) recorded within 5 minutes after administration of regadenoson. Change in sys-
tolic blood pressure (changeSBP) was calculated by subtracting resting (restingSBP) from peak
systolic blood pressure (peakSBP) recorded within 5 minutes after administration of regadeno-
son. Maximal predicted heart (MHR) rate was calculated using 220-age (years) and percent
maximal predicted heart rate (%MPHR) was calculated by peakHR over MHR and multiplying
by 100 (%MPHR = (peakHR/MHR)100). Percent change in heart rate (%ChangeHR) was cal-
culated by changeHR over restingHR and multiplying by 100. Incidence of patient reported
side effects were prospectively recorded (dyspnea, nausea, flushing, dizziness, abdominal pain,
headache, chest pain).
Non-coffee drinkers (group 1) were compared to subjects who had consumed coffee
within 12 to 24 hours (group 2) or more than 24 hours (group 3) prior to regadenoson
administration.
Statistical Analysis
Baseline demographic and clinical variables are descriptively summarized. Continuous vari-
ables are expressed as mean ± SD. Categorical data are presented as percent frequency.
Unpaired two-sided Student’s t-test was used to compare normally distributed continuous data
between two groups. One-way analysis of variance test (ANOVA) and post hoc Tukey compar-
isons were used to determine difference between different groups based on coffee consumption.
Categorical variables were compared using the χ2 test and continuous variables were computed
using student t test. Statistical significance was defined as p-value< 0.05.
Multivariable linear regression with change in systolic blood pressure (SBP), HR, and per-
cent maximal predicted heart rate achieved at peak exercise as outcome variables was per-
formed for non-coffee drinkers, subjects exposed to coffee 12 to 24 hours and more than
24 hours before regadenoson administration. Exposure to coffee 12 to 24 hours prior was used
as the reference category. Adjustment for known confounders was based on clinical variables
known to affect caffeine metabolism, as well as clinical variables with p<0.1 in univariable
analysis and if adjustment for the variables resulted in at least a 10% change in the estimate of
the overall association.
Results
Baseline characteristics of the study subjects are described in (Table 1). Subjects mean age was
60±11 years. Among the subjects, 257 (78%) were coffee drinkers while 73 subjects denied any
coffee consumption. Non-coffee drinkers tended to be younger (57.2±10.5 vs. 60.9±10.5 years,
p = 0.01), more obese (105.7±30.7 vs.97.3±23.5 Kg., p = 0.014), consumed less chocolate
(69.9% vs. 80.9%, p = 0.042), had more GERD (41.1% vs. 28.4%, p = 0.039) and were less fre-
quently prescribed antiplatelet medication (37% vs. 52.9%, p = 0.016) as compared to coffee
consumers. Twelve coffee drinkers did not report when they last consumed coffee. None of the
subjects was taking theophylline. Table 1 summarizes baseline characteristics between non-
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coffee drinkers (group 1), subjects who drank coffee 12–24 hours prior (group 2) and those
who drank coffee more than 24 hours to stress testing (group 3).
SBP change (15.2±17.1 vs. 7.2±10.2 mmHg, p = 0.001), HR change (32.2±14 vs. 27.3±9.6
bpm, p = 0.038) and %MPHR (65.5±15.6 vs. 60.7±8.6%, p = 0.038) were significantly higher in
non-coffee drinkers (group 1) compared to those who drank coffee 12–24 hours prior (group















Patients 332 73 108 139
Age (years) 60±10.6 57.2±10.5 62±9.9 59.8±10.6 0.007 0.208 0.215 0.01
Male (%) 145 (43.7) 35 (47.9) 48 (44.4) 57 (41) 0.643 0.333 0.588 0.616
White (%) 232 (69.6) 48 (65.8) 88 (81.5) 89 (64) 0.018 0.803 0.003 0.007
Weight (kg) 99.2±25.4 105.7±30.7 95.9±20.6 98.5±25.7 0.033 0.132 0.710 0.04
Height (cm) 168.4
±10.9
169.8±11.1 168.9±11.7 167.3±10.6 0.865 0.260 0.477 0.245
BMI 35±8.7 36.7±10.1 33.6±6.9 35.3±9.2 0.057 0.522 0.295 0.065
Soft drink (%) 213 (64.5) 50 (68.5) 67 (62) 92 (66.2) 0.373 0.734 0.499 0.643
Chocolate (%) 259 (78) 51 (69.9) 84 (77.8) 115 (82.7) 0.232 0.033 0.330 0.098
Active smoking (%) 107 (32.4) 24 (33.3) 39 (36.1) 42 (30.2) 0.702 0.643 0.328 0.618
Alcohol (%) 107 (30) 22 (30.6) 37 (35.2) 47 (34.3) 0.517 0.584 0.880 0.798
Coronary artery disease (%) 100 (30.1) 16 (21.9) 43 (39.8) 39 (28.1) 0.013 0.334 0.053 0.026
Coronary artery bypass grafting (%) 32 (9.6) 8 (11) 13 (12) 11 (7.9) 0.824 0.463 0.281 0.537
Past myocardial infarction (%) 67 (20.2) 13 (17.8) 28 (25.9) 25 (18) 0.203 0.974 0.133 0.247
Congestive heart failure (%) 31 (9.3) 10 (13.7) 9 (8.3) 11 (7.9) 0.252 0.185 0.905 0.351
Diabetes mellitus (%) 132 (39.8) 26 (35.6) 42 (38.9) 59 (42.4) 0.656 0.336 0.573 0.614
Hypertension (%) 263 (79.2) 57 (78.1) 84 (77.8) 113 (81.3) 0.961 0.577 0.495 0.757
Atrial ﬁbrillation/ﬂutter (%) 42 (12.7) 11 (15.1) 11 (10.2) 19 (13.7) 0.327 0.781 0.407 0.579
Chronic obstructive pulmonary
disease (%)
73 (22) 15 (20.5) 24 (22.2) 33 (23.7) 0.788 0.598 0.779 0.866
Asthma (%) 72 (21.7) 11 (15.1) 27 (25) 28 (20.1) 0.111 0.366 0.364 0.265
Stroke (%) 36 (10.8) 10 (13.7) 9 (8.3) 16 (11.5) 0.252 0.645 0.413 0.504
Chronic kidney disease (%) 11 (3.3) 4 (5.5) 3 (2.8) 3 (2.2) 0.364 0.214 0.754 0.405
Gastroesophageal reﬂux disease (%) 103 (31) 30 (41.1) 15 (13.9) 56 (40.3) <0.001 0.909 <0.001 <0.001
Hyperlipidemia (%) 229 (69) 53 (72.6) 80 (74.1) 90 (64.7) 0.826 0.247 0.118 0.237
Peripheral vascular disease (%) 38 (11.4) 8 (11) 10 (9.3) 17 (12.2) 0.708 0.785 0.459 0.759
Antiplatelet (%) 163 (49.1) 27 (37) 66 (61.1) 65 (46.8) 0.002 0.173 0.026 0.004
Beta blockers (%) 155 (46.7) 32 (43.8) 54 (50) 66 (47.5) 0.416 0.256 0.695 0.718
Calcium channel blockers (%) 88 (26.5) 16 (22.2) 34 (31.5) (25.9) 0.176 0.557 0.335 0.364
Statins (%) 159 (47.9) 33 (45.2) 55 (50.9) 66 (47.5) 0.450 0.752 0.591 0.737
Proton-pump inhibitors (%) 102 (30.7) 23 (31.9) 32 (29.6) 46 (33.1) 0.741 0.866 0.561 0.843
Diuretics (%) 136 (41) 27 (37.5) 37 (34.3) 67 (48.2) 0.656 0.139 0.028 0.068
ACEI-ARB (%) 152 (45.8) 32 (44.4) 43 (39.8) 71 (51.1) 0.537 0.361 0.079 0.205
H2-Blockers (%) 24 (7.2) 5 (6.9) 6 (5.6) 11 (8) 0.704 0.071 0.461 0.760
Angiotensin-converting enzyme inhibitor. ARB: Angiotensin receptor blocker
1 Comparison between non-coffee drinker (group 1) and subject who drank coffee 12–24 hours prior (group 2)
2 Comparison between non-coffee drinker (group 1) and subjects who drank coffee more than 24 hours prior (group 3)
3 Comparison between subjects who drank coffee 12–24 hours (group 2) and subjects who drank coffee more than 24 hours prior (group 3)
4 Comparison between group 1, 2 and 3
doi:10.1371/journal.pone.0130487.t001
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2). %Change HR (44.8±19.7 vs. 40.7±15.76%, p = 0.377) was not significantly different between
group 1 and 2.
There was no significant difference in SBP change (15.2±17.1 vs. 13.01±15.8 mmHg,
p = NS), HR change (32.2±14 vs. 32.1±15.3 bpm, p = NS), %MPHR (65.5±15.6 vs. 64.3±13.6%,
p = NS), and %Change HR (44.8±19.7 vs. 46.8±23.7%, p = NS) between non-coffee drinkers
(group 1) and those who drank coffee>24 hours prior (group 3). Moreover, subjects who
drank coffee>24 hours prior (group 3) exhibited higher SBP change (13±15.8 vs. 7±10.2,
p = 0.007) and HR change (32.1±15.3 vs. 27.3±9.6, p = 0.017) as compared to those who drank
coffee 12–24 hours prior to testing (group 2). MPHR (64.3±13.6 vs. 60.7±8.6%, p = 0.077) and
%Change HR (46.82±23.7 vs. 40.7±15.76%, p = 0.053) were higher among group 3 compared
to group 2 but failed to achieve statistical significance (Table 2) (Fig 1).
After adjusting for age, race, weight, chocolate consumption, diuretics use, history of coro-
nary artery disease, past myocardial infarction, asthma, calcium channel blocker and beta
blocker use, Change SBP (p = 0.003), Change in HR (p = 0.046) and %MPHR (p = 0.015)
remained significantly different between non-coffee drinkers (group 1) and subjects who con-
sumed coffee 12–24 hours prior (group 2) in multivariable regression analysis. Moreover, on
multivariable regression analysis, Change SBP (p = 0.031), Change HR (p = 0.019), and %
Change HR (p = 0.041) remained significantly different between subjects who drank coffee 12–
24 hours (group 2) and subjects who drank coffee more than 24 hours prior.
Among subjects who drank coffee 12–24 hours (group 2) prior to regadenoson administra-
tion, the number of coffee drinks did not have any effect on Change HR, Change SBP, MPHR
and %Change HR (Table 3).
The number of self-reported adverse effects was lower in subjects exposed to caffeine 12–
24 hours prior to regadenoson (group 2), as compared to>24 hours prior (group 3, or caffeine
naïve subjects (group 1)(1.35±1.1 vs. 1.94±1.4 vs. 1.79±1.4; p = 0.002). Group 2 developed
less abdominal pain (0.9% vs 16.4% vs. 14.4%, p<0.001), nausea (12% vs. 28.8% vs. 26.6%,
p = 0.007) and dizziness (17.6% vs. 32.9% vs. 38.1%, p = 0.002) when compared to groups 1
and 3.
Table 2. Hemodynamic Effects of Regadenoson According to Coffee Consumption.
Non Coffee drinkers 12–24 hours hold >24 hours hold P Value1 P Value2 P Value3 P Value4
Baseline HR (bpm) 73.3±12.0 69.3±11.9 71.4±14.3 0.107 0.587 0.402 0.121
Peak HR (bpm) 105.5±19.5 96.5±14.1 103.4±20.5 0.004 0.709 0.010 0.002
HR change (bpm) 32.3±14.0 27.3±9.6 32.1±15.3 0.038 0.992 0.017 0.010
Baseline SBP (mmHg) 131.6±20.9 139±22.8 135.3±21.0 0.070 0.470 0.388 0.084
Baseline DBP (mmHg) 82.1±16.7 78.1±11.2 79.3±12.6 0.287 0.623 0.734 0.143
Peak SBP (mmHg) 145.2±24.6 145.5±21.9 151.7±46.6 0.994 0.791 0.667 0.289
Peak DBP (mmHg) 82±13.9 76.9±12.4 80.9±12.3 0.024 0.820 0.041 0.014
Change in SBP (mmHg) 15.2±17.1 7.2±10.2 13.0±15.8 0.001 0.574 0.007 0.001
Change in DBP (mmHg) 0.96±12.5 -0.97±6.6 1.5±12.1 0.482 0.946 0.191 0.206
% MPHR 65.5±15.7 60.7±8.6 64.3±13.6 0.038 0.791 0.077 0.026
%Change HR 44.8±19.7 40.7±15.8 46.8±23.7 0.38 0.779 0.053 0.065
HR: heart rate. SBP: systolic blood pressure. DBP: diastolic blood pressure. MPHR: maximal predicted heart rate. % ChangeHR: percent change in heart
rate
1 Comparison between non-coffee drinker (group 1) and subject who drank coffee 12–24 hours prior (group 2)
2 Comparison between non-coffee drinker (group 1) and subjects who drank coffee more than 24 hours prior (group 3)
3 Comparison between subjects who drank coffee 12–24 hours (group 2) and subjects who drank coffee more than 24 hours prior (group 3)
4 Comparison between group 1, 2 and 3
doi:10.1371/journal.pone.0130487.t002
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Discussion
In our study, subjects who were coffee naive (group 1) or those who consumed coffee more
than 24 hours prior (group 3) demonstrated significantly larger change in heart rate and
Fig 1. Regadenoson Effect on SBP change, HR change, %MPHR and% changeHR According to Coffee Consumption.Group 1: non-coffee drinkers;
Group 2: subjects who drank coffee 12–24 hours prior to stress test; Group 3: subjects who drank coffee more than 24 hours prior to stress test. Error bars
correspond to 95% confidence interval.
doi:10.1371/journal.pone.0130487.g001
Table 3. Coffee Consumption Among GroupWith 12–24 Hour Hold.
Number of coffee cups consumed (n = 108) 1 (n = 5) 2 (n = 44) 3 (n = 36) 4 (n = 23) P value1
HR_change (bpm) 27.3±3.3 27.5±8.8 27.4±9.5 26.7±11.9 0.990
SBP_change (mmHg) 5.5±6.8 6.7±10.5 9.0±11.9 5.6±6.8 0.603
% MPHR 59.7±5.3 60.2±7.7 61.7±9.5 60.3±9.2 0.858
%Change HR 40.0±11.9 42.9±16.3 39.7±17.7 40.7±15.7 0.630
HR: heart rate. SBP: systolic blood pressure. MPHR: maximal predicted heart rate. % ChangeHR: percent change in heart rate
1Comparison among group 2 (12–24 hour caffeine hold) based on number of coffee drink consumed
doi:10.1371/journal.pone.0130487.t003
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systolic blood pressure when compared to subjects exposed to coffee within 12–24 hours
(group 2) prior to regadenoson exposure.
The blunted rise in heart rate and systolic blood pressure observed in subjects with recent
exposure to caffeine may be attributed to the long caffeine half-life in some patients. Caffeine
(1,3,7-trimethylxanthine) bioavailability is 100%, with peak level achieved within 15 to 45 min-
utes [12]. It is metabolized predominantly by cytochrome P450 (CYP1A2 isoenzyme) with a
half live (t1/2) ranging between 2 to 12 hours [12,13]. Many conditions and medications have
been reported to affect caffeine metabolism and potentially affect its half-life. CYP450 inhibi-
tors such as cimetidine, oral contraceptive usage, pregnancy, and alcoholic liver disease can
increase caffeine half-life [14–16]. CYP450 inducers, such as phenytoin, phenobarbital, or
rifampin, as well as smoking have been associated with a shortened caffeine half-life [17–18].
Caffeine is metabolized into 3 active metabolites: paraxanthine (1,7-dimethylxanthine), theo-
bromine (3,7-dimethylxanthine) and theophylline (1,3-dimethylxatnhine)[19]. In humans,
these metabolites account for 84%, 12% and 12% of caffeine metabolism respectively [20]. The
half-life of paraxanthine, theobromine and theophylline can be as high as 4, 7 and 6 hours
respectively, and these active metabolites can therefore extend the biologic effects of caffeine
exposure [21].
Caffeine is a competitive inhibitor of adenosine A1, A2A and A2B receptors [22]. Chronic
inhibition of adenosine receptors by caffeine results in increased sensitivity and up-regulation
of those receptors [23,24]. Selective A2A receptors agonists, like regadenoson, are believed to
increase heart rate by a reflex increase in sympathetic activity triggered by their vasodilatory
effect on peripheral A2A receptors [25]. However, more recent evidence indicates a chemore-
ceptor mediated activation of the sympathetic nervous system and release of catecholamines
[26,27]. In the coronary circulation, there is a high reserve for A2A receptor mediated coronary
vasodilation with 25% receptor occupancy by regadenoson translating into 90% maximal vaso-
dilation [10,28]. Thus minimal competitive inhibition by caffeine has been thought not to sig-
nificantly impact maximal myocardial blood flow. In contrast, in the peripheral vasculature,
A2A receptor reserve may be lower, thus possibly explaining a blunted increase in heart rate in
response to regadenoson in subjects exposed to caffeine [10]
In addition, A2A receptors are present in the atrium and are able to activate ryanodine
receptors [29]. Ryanodine receptor activation and subsequent calcium release mediates beta
adrenergic heart rate stimulation [30]. A2A receptor agonists have been shown to modulate
the response to beta adrenergic stimulation by attenuating the effect of A1 receptor and
increasing contractility directly [31]. Therefore it is possible that caffeine exposure and partial
inhibition of A2A receptors leads to decreased ryanodine receptor activation and blunting of
beta adrenergic response mediated by A1 receptor. Our study findings suggest that consump-
tion of caffeine within 24 hours may inhibit the vasodilatory properties of regadenoson admin-
istered for MPI. Moreover altered heart rate and blood pressure response could have been in
response to a combination of altered sympathetic tone, variable chemoreceptor response, and
vasodilatory effects by caffeine and regadenoson. We observed a decreased incidence of patient
reported side effects in subjects exposed to caffeine between 12–24 hours supporting the possi-
bility that residual caffeine activity attenuates the biologic response to regadenoson within this
time window. It has been previously demonstrated that caffeine administered in doses of 200
or 400mg 90 minutes before regadenoson significantly reduces the sensitivity of MPI [11]. Fol-
lowing caffeine administration the mean number of reversible defects identified was reduced
by approximately 60% [11]. It is therefore possible that based on variations in caffeine metabo-
lism, exposure to caffeine between 12–24 hours before regadenoson could also reduce the sen-
sitivity of regadenoson MPI. It may be necessary to hold caffeine consumption for 24 hours
prior to regadenoson MPI to avoid any residual interaction.
Caffeine and Regadenoson Response
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Our study had many limitations. First, we did not measure blood caffeine level and thus we
did not assess the association between serum caffeine level and effect on HR, BP and %MPHR
response. Second, patient recall bias of caffeine consumption might have contributed to our
results. We could not control for the potential possibility of patients underreporting their caf-
feine consumption in order to avoid stress test delay or cancelation. Altered sympathetic tone,
variable chemoreceptor response, as well as vasodilatory effects by caffeine and regadenoson
could have contributed to changes in heart rate and blood pressure response. Moreover, it is
difficult to assess variations in caffeine dosing based on beverage types.
Conclusions
Caffeine exposure within 12–24 hours prior to regadenoson MPI seems to attenuate the hemo-
dynamic effect of regadenoson as indicated by blunting of heart rate and systolic blood pres-
sure rise. Further studies are needed to examine the possible impact of caffeine exposure within
12–24 hours as currently endorsed in the FDA label on diagnostic sensitivity and specificity of
regadenoson stress imaging.
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